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Summary 27 
Large-scale phenotyping efforts have demonstrated that approximately 25-30% of mouse 28 
gene knockouts cause intra-uterine lethality. Analysis of these mutants has largely focussed 29 
on the embryo but not the placenta, despite the critical role of this extra-embryonic organ for 30 
developmental progression. Here, we screened 103 embryonic lethal and subviable mouse 31 
knockout lines from the Deciphering the Mechanisms of Developmental Disorders 32 
programme (https://dmdd.org.uk) for placental phenotypes. 68% of lines that are lethal at or 33 
after mid-gestation exhibited placental dys-morphologies. Early lethality (E9.5-E14.5) is 34 
almost always associated with severe placental malformations. Placental defects strongly 35 
correlate with abnormal brain, heart and vascular development. Analysis of mutant 36 
trophoblast stem cells and conditional knockouts suggests primary gene function in 37 
trophoblast for a significant number of factors that cause embryonic lethality when ablated. 38 
Our data highlight the hugely under-appreciated importance of placental defects in 39 
contributing to abnormal embryo development and suggest key molecular nodes governing 40 
placentation. 41 
 42 
 43 
  44 
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Systematic identification of genes required for normal embryogenesis is essential if we are to 45 
successfully unravel the molecular framework underpinning embryo development. Such 46 
knowledge will help identify genetic causes of developmental abnormalities that manifest 47 
during pregnancy or at birth, and comprise a significant health burden. Large-scale 48 
phenotyping efforts have consistently found that 25-30% of mouse gene knockouts (KOs) 49 
result in non-viable offspring1-5. In almost all studies of developmentally critical genes, 50 
research has focussed on the impact of the mutation on the embryo. By comparison, little 51 
attention has been paid to possible effects of these mutations on extra-embryonic tissues, 52 
almost certainly resulting in under-representation of placental phenotypes in public databases. 53 
The Mouse Genome Informatics (MGI) database, for example, shows extra-embryonic 54 
defects in only 10% of embryonic lethal strains. Gaining a more accurate view of the actual 55 
frequency of placental abnormalities is critically important for our understanding of the 56 
contribution of this vital organ to the aetiology of developmental defects and congenital 57 
abnormalities6. 58 
Several ground-breaking studies have highlighted the essential role of extra-embryonic 59 
tissues for normal development and long-term health. Placental insufficiency results in 60 
intrauterine growth retardation and, as a consequence, can cause fetal programming effects 61 
that predispose to later-onset disease7,8. Moreover, tetraploid complementation9 or conditional 62 
gene ablation experiments have identified embryonic lethal phenotypes where normal 63 
development can be entirely rescued solely by providing the embryo with a wild-type 64 
placenta10-15. 65 
However, systematic efforts to discover genes required for normal placental development 66 
are still missing. The DMDD consortium16 is one of several ongoing programmes dedicated 67 
to identifying and characterising embryonic lethal genes in the mouse. In addition to detailed 68 
phenotypic assessment of structural abnormalities in mutant embryos, DMDD also 69 
investigates the impact of each mutation on placental development. Here we report the 70 
analysis of placental morphology for 103 such lines. Our results reveal a dramatically higher 71 
rate of placental phenotypes than had been previously appreciated, and a striking association 72 
of placental defects with specific abnormalities in the embryo itself. Our study identifies the 73 
placenta as a pivotal target organ for the effects of gene mutations contributing to 74 
developmental demise. 75 
 76 
Results 77 
Placental defects in embryonic lethals 78 
We analysed 103 mouse KO lines that fail to produce mutant offspring at the expected 79 
Mendelian frequency at postnatal day (P)14, but yielded mutant embryos at either embryonic 80 
day (E)14.5 or E9.5. Lines for which mutant conceptuses could not be recovered at E9.5 were 81 
not included in this screen. Of the 103 lines analysed, 82 were classified as P14 lethal, since 82 
no mutant offspring were recovered at that stage. The remaining 21 lines were termed 83 
subviable, with mutant pups constituting 13% or less of all offspring obtained, a proportion 84 
significantly below the 25% expected from heterozygous crosses (Fig. 1a, Supplementary 85 
Table 1). Similar criteria were applied to further sub-categorise the P14 lethal group 86 
according to viability at E14.5 (Fig. 1a). 87 
Placentas of all lines were subjected to histopathological analysis at E9.5, E14.5 or both 88 
(Supplementary Table 1). As expected, less than 1% of wild-type placentas showed an 89 
abnormal phenotype. By contrast, in mutant placentas we detected dys-morphologies in 56/82 90 
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(68%) of P14 lethal strains (Fig. 1b). Even when including the P14 subviable lines, the 91 
placental phenotype rate was still 59%, a far higher frequency than the ~10% annotated in 92 
MGI (Fig. 1b). All genes associated with placental abnormalities in mutants were expressed 93 
in the trophoblast lineage of this organ (Extended Data Fig. 1a), lending support to the notion 94 
that they contribute directly to placental growth or function. 95 
We also assessed the conceptuses for yolk sac defects, an extra-embryonic structure that 96 
is especially important for nutrient provision during the first half gestation, before formation 97 
of the functional placenta at E9.5 (Supplementary Table 1). Since yolk sac was routinely used 98 
for genotyping it proved only possible to analyse this tissue in 66 lines. Amongst these, an 99 
abnormal yolk sac morphology was detected in 11% (7/66) of cases, compared to ~6% 100 
annotated amongst prenatal lethals in the MGI database. Strikingly, all 7 affected lines fell 101 
within the E9.5-E14.5 lethal group (7/24=29%; Fig. 1c). Thus, whilst yolk sac defects 102 
affecting its structure or hematopoietic function may contribute to the lethality of some of 103 
these early lethal strains, they occur at a much lower frequency than placental abnormalities.  104 
When scoring the occurrence of placental defects as a function of developmental stage, 105 
we found that almost every line that died before E14.5 exhibited placental abnormalities 106 
(40/41; Fig. 1d; Extended Data Fig. 1b), compared to only 35% of lines that were viable 107 
beyond E14.5 (12/34) (Fig. 1d; Supplementary Table 1). These findings demonstrate that 108 
mutations resulting in embryonic lethality between E9.5-E14.5 are almost certainly associated 109 
with a defective placenta.  110 
In line with the placenta being the essential nutrient-supplying organ from mid-gestation 111 
onwards, we also found that mutant E14.5 embryos in strains exhibiting a placental phenotype 112 
were shifted to a younger developmental stage compared to those in which placental 113 
development was normal (Fig. 1e; Extended Data Fig. 1c)17. 114 
 115 
Categories of placental defects 116 
In order to categorise the different types of defect, we examined the three main layers of the 117 
mature placenta: the labyrinth, which constitutes the main nutrient and gas exchange surface; 118 
the junctional zone consisting of spongiotrophoblast, glycogen cells and different giant cell 119 
subtypes; and the maternally derived decidua (Fig. 2; Extended Data Fig. 2a).  120 
Haematoxylin & Eosin histology (Extended Data Fig. 2b, c) was complemented with 121 
three histological staining methods to accurately classify the cellular and tissue composition 122 
defects in abnormal placentas using a series of phenotype criteria (Fig. 2a, b). At E9.5, a 123 
frequently detected malformation affected the invagination of allantoic blood vessels into the 124 
chorionic ectoderm, a process critical for development of the labyrinth that will almost 125 
certainly result in developmental arrest (Fig. 2a, c; Extended Data Fig. 2b). At E14.5, by far 126 
the most prevalent abnormalities were defects in the growth and intricate organisation of the 127 
fetal and maternal blood conduits within the labyrinth layer (Fig. 2b, d; Extended Data Fig. 128 
2c). Since these abnormalities diminish the surface area available for nutrient transport, they 129 
will compromise fetal growth and survival.  130 
Collectively these histological characterisations of >300 mutant placentas provide a vast 131 
resource for the research community, with all data available at https://dmdd.org.uk. 132 
 133 
Critical nodes in placental development 134 
We next examined whether the identity of genes associated with placental defects suggested 135 
specific molecular pathways that may be pivotal for the formation or function of this organ. 136 
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For genes affecting placental morphology at E9.5 in mutants, this network analysis 137 
highlighted several functional gene clusters centred around L3mbtl2, Bap1 and Arhgef7 (Fig. 138 
2e; Extended Data Fig. 1d). Similarly, several factors identified in the E14.5 analysis formed 139 
specific molecular nodes, for example around Traf2, Nek9 and Rpgrip1l (Extended Data Fig. 140 
1d). Although relatively few genes have been analysed for defects in extra-embryonic tissues 141 
in the literature, it is obvious that a large fraction of network components identified in our 142 
analyses have been associated with embryonic phenotypes. It therefore seems highly likely 143 
that mutants for many of these functionally connected genes will also exhibit placental 144 
abnormalities. 145 
 146 
Embryo and placenta defects are linked 147 
Since the DMDD programme scores both embryo and placental defects, it provides a unique 148 
opportunity to assess co-associations between specific phenotypes18,19. Importantly, DMDD 149 
phenotype calls are based on precise embryo sub-staging, therefore the analysis excludes any 150 
apparent phenotypes that simply reflect the developmental delay prevalent amongst embryos 151 
with placental defects. Nevertheless, mutant mouse lines exhibiting placental abnormalities 152 
were enriched for specific E14.5 embryo phenotypes that were distinct from those with 153 
normal placentas (Extended Data Fig. 3a).  154 
Embryo phenotype categories showing significant statistical correlation with placental 155 
defects included abnormalities in the heart, brain and vascular system (Fig. 3a; Extended Data 156 
Figs. 3b and 4a, b; Supplementary Table 2). In particular, this affected anomalies in forebrain 157 
development, heart chamber and septum morphology, subcutaneous edema, and overall artery 158 
or vein topology (Fig. 3b-d; Extended Data Fig. 4c, d). These phenotype co-associations 159 
suggest co-regulatory or inter-dependent mechanisms during the development of particular 160 
organ systems, notably between the placenta and morphogenesis of the brain, heart and 161 
vascular system. 162 
 163 
Trophoblast-specific gene functions 164 
Since the placenta comprises cell types of distinct lineage origins, a placental phenotype may 165 
be caused by trophoblast-intrinsic and/or extra-embryonic mesoderm-derived endothelial cell 166 
defects. To determine trophoblast-specific functions of genes identified as important for 167 
placental development, we used CRISPR-Cas9 mediated ablation in trophoblast stem cells 168 
(TSCs; Extended Data Fig. 5)20,21. We chose three genes for this analysis that caused lethality 169 
around E9.5-10.5 when ablated; the tumour suppressor BRCA1 associated protein 1 (Bap1), 170 
the Crumbs epithelial cell polarity complex family member 2 (Crb2), and the nucleotide 171 
binding protein-like factor (Nubpl) (Extended Data Fig. 6)22.  172 
Nubpl-mutant TSCs exhibited a decreased stem cell potential, as evidenced by lower 173 
expression levels of Cdx2, Esrrb and Elf5, which may explain the dramatic size reduction of 174 
the trophoblast compartment in Nubpl-/- placentas. Moreover, severely impaired up-regulation 175 
of Gcm1 (an early marker of syncytializing trophoblast) and lower expression levels of Syna 176 
and, to a lesser extent, Synb showed that differentiation towards the syncytiotrophoblast 177 
lineage was inhibited in the absence of Nubpl (Fig. 4a; Extended Data Fig. 7a). We also 178 
detected a prominent phenotype in Bap1-deficient TSCs, as they displayed elevated 179 
expression of the key stem cell markers Cdx2 and Esrrb when grown under self-renewal 180 
conditions. When triggered to differentiate, Bap1-/- TSCs failed to up-regulate markers of 181 
syncytiotrophoblast, sinusoidal trophoblast giant cells and glycogen cells (Fig. 4b; Extended 182 
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Data Fig. 7b). These TSC differentiation defects may well contribute to the labyrinth 183 
formation phenotype evident in both Nubpl and Bap1 mutants. By contrast, Crb2-null TSCs 184 
were indistinguishable from wild-type (empty vector) controls (Extended Data Fig. 7c).  185 
 186 
Lineage origins of placental defects 187 
To gain further insights into trophoblast-intrinsic versus embryonic lineage-induced 188 
effects, we chose the same three genes that we studied in TSCs for conditional gene ablation 189 
in vivo. Thus, we used the Sox2-Cre transgene to remove their function in the embryo, while 190 
leaving expression intact in the trophoblast-derived cells of the placenta and the visceral yolk 191 
sac endoderm (Fig. 5a)23.  192 
Nubpl null embryos associated with a heterozygous placenta were significantly more 193 
advanced in development than their complete KO counterparts at E9.5 and could still be 194 
recovered up to E11.5, a stage when the complete KO was already resorbed (Fig. 5a; 195 
Extended Data Fig. 8a). Histological examination of the E9.5 and E11.5 placentas showed 196 
that the trophoblast expansion, syncytiotrophoblast differentiation and labyrinth 197 
vascularisation defects were seemingly fully rescued in the conditional KOs (cKOs) (Fig. 5b; 198 
Extended Data Fig. 8b). This rescue was also suggested by the transcriptome-wide similarity 199 
between cKO and wild-type or heterozygous control placentas (Extended Data Fig. 9a). Thus, 200 
although the conditional Nubpl mutation is still lethal beyond E11.5 due to an essential role of 201 
this gene in the embryo proper, a functional trophoblast lineage rescues the placental 202 
phenotype and the resulting early mid-gestation embryonic lethality.  203 
For Bap1, syncytiotrophoblast formation was partially restored in cKO placentas. 204 
Furthermore, global expression profiles of Bap1 cKO placentas were more similar to controls 205 
than to KOs (Extended Data Fig. 9a, b). However, placental vascularisation remained under-206 
developed and the conceptuses still died at mid-gestation (Extended Data Fig. 9b). This 207 
indicates an essential additional function of Bap1 in the extra-embryonic mesoderm 208 
compartment that prevents placental labyrinth formation and also results in a yolk sac defect 209 
in KOs and cKOs (Extended Data Fig. 10a). Similarly, Crb2 null embryos could not be 210 
rescued by a genetically functional trophoblast lineage (Extended Data Fig. 10b), a result 211 
consistent with the lack of phenotype in mutant TSCs. Since the yolk sac phenotype also 212 
remained unchanged in cKOs, it can be concluded that the chorio-allantoic placentation defect 213 
is due to the critical role of Crb2 in mesoderm development24.  214 
In summary, in vitro and in vivo analysis of 3 genes whose mutation causes mid-215 
gestational lethality identified 2 factors (Nubpl and Bap1) with important roles in the proper 216 
expansion and differentiation capacity of trophoblast cells. One of these (Nubpl) is indeed 217 
causative of the embryonic lethal phenotype at E9.5. 218 
 219 
Discussion 220 
Systematic mouse KO phenotyping efforts undertaken to date have excluded the analysis of 221 
extra-embryonic tissues, most notably the placenta3-5,25. Ignoring placental defects as a major 222 
contributory factor to fetal demise has previously led to several prominent examples of mis-223 
annotation of gene function, such as for the tumour suppressor Rb and the oncogene c-myc26-224 
29. In both cases, subsequent studies revealed that restoring gene function to the trophoblast 225 
lineage could largely rescue the embryonic defects observed30,31. Here, we report the first 226 
systematic effort to assess the prevalence of placental abnormalities in P14 lethal or subviable 227 
mouse mutants that survive to at least mid-gestation.  228 
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We find a remarkably high percentage of placental abnormalities amongst these lines, 229 
with two-thirds of all P14 lethal strains exhibiting obvious defects. In particular, KOs 230 
resulting in mid-gestational lethality are almost certainly associated with an abnormal 231 
placenta, underpinning the notion that defects in placentation create a bottleneck for 232 
developmental progression past mid-gestation32. This frequency of placental defects illustrates 233 
the hugely under-estimated impact of gene mutations on extra-embryonic tissues. Given that 234 
approximately 25-30% of all mutations cause embryonic lethality, our data suggests that a 235 
placental phenotype has gone unnoticed and unreported in hundreds if not thousands of 236 
mutant strains. 237 
Many of the genes associated with placental defects in our screen are part of specific 238 
functional hubs, such as the L3mbtl2 Polycomb group complex and the tumour necrosis 239 
factor-receptor associated factor (Traf2) network, which appear to be of major importance for 240 
placental development. Identification of such molecular nodes holds great promise as a way 241 
of gaining novel insights into the causes of placentation defects in humans. Consistent with 242 
this, at least three of the genes we assessed, TRAF2, PSPH and BAP1 (through its established 243 
interaction with ASXL3) have been implicated in the pathophysiology of human pregnancy 244 
disorders, many of which have their origin in defective placentation33-36.  245 
A unique feature of our study is the integrated analysis of both embryo and placenta. This 246 
has revealed significant co-associations between the occurrence of a placental phenotype and 247 
particular defects within the embryo itself, notably affecting neurodevelopment, the heart, and 248 
the overall vascular system. A placenta-heart axis has been recognised before37-40, however, 249 
we can now identify highly specific pathologies such as a double outlet right ventricle and 250 
ventricular septal defects that strongly correlate with the presence of an abnormal placenta. 251 
Effects of placental insufficiency on brain development have also been reported31,41,42; our 252 
large-scale screen provides strong correlative evidence to support this developmental co-253 
relationship. By contrast, a systematic impact of the placenta on vascular development, 254 
beyond overall hemodynamics43, has not previously been recognised. The significance of our 255 
findings may therefore extend not only through the immediate gestational period, but also into 256 
post-natal life and may help explain how placental insufficiency can have long-lasting 257 
consequences on cardiovascular disease risk, outweighing other behavioural factors44. 258 
Taken together, in this study we demonstrate that placental malformations are far more 259 
common than previously thought in embryonic lethal mutations and co-occur specifically 260 
with heart, brain and vascular network defects. Our data highlight the importance of including 261 
extra-embryonic tissues in studies investigating the genetic basis of congenital abnormalities.  262 
 263 
 264 
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Figure legends 403 
Figure 1. Placental defects are highly prevalent in gene mutants that affect embryonic 404 
viability. (a) Summary of the 103 mouse lines screened. E: day of embryonic development; 405 
P: day of postnatal development. ‘Subviable’ identifies strains in which the proportion of 406 
mutant offspring is >0% but ≤13%. (b) Summary of non-viable mouse lines in which a 407 
placental phenotype has been annotated in Mouse Genome Informatics (MGI; 408 
http://www.informatics.jax.org) and in our DMDD programme. (c) Yolk sac appearance in 409 
wild-type (WT) and Dennd4c mutants. Images are representative of 3 independent mutants 410 
and >60 WT samples analysed. Sections were stained for E-Cadherin (green, demarcating the 411 
visceral endoderm) and Laminin (red, highlighting the basement membrane). Arrows point to 412 
the disconnected mesoderm and endoderm layers in mutants. (d) Breakdown of the proportion 413 
of placental phenotypes by stage of embryonic lethality. (e) Developmental progression of 414 
mutant embryos depending on presence or absence of a placental phenotype. TS: Theiler 415 
stage. 416 
 417 
Figure 2. Summary of common placental defects and functional networks. (a) Common 418 
phenotype criteria used to assess E9.5 mutant placentas (red = abnormality detected). TGC: 419 
trophoblast giant cell. (b) E14.5 placental phenotypes in mutant strains. SpT: 420 
spongiotrophoblast; Lab: labyrinth. (c) Top: Schematic representation of main structures of an 421 
E9.5 placenta. Below: In situ hybridisation for spongiotrophoblast marker Tpbpa and 422 
immunostaining against E-Cadherin (Cdh1) on WT and mutant placentas, as indicated. Large 423 
red arrows highlight Tpbpa-positive cells. Small red arrows in the Cdh1-stained WT placenta 424 
highlight nucleated blood cells in fetal blood vessels; arrowheads in the Pigl-/- placenta 425 
demarcate sites of chorionic ectoderm invagination but absence of blood vessels. (d) Top: 426 
Schematic representation of main structures of an E14.5 placenta. Below: Examples of 427 
histological analyses of E14.5 WT and mutant placentas: Tpbpa in situ hybridisation, red 428 
vertical line shows thickness of junctional zone. BSI-B4 isolectin staining demarcating the 429 
three main placental layers; red rectangle highlights the severely reduced complexity of 430 
labyrinth vascularisation in the Traf2 mutant. E-Cadherin (Cdh1) immunohistochemistry 431 
labelling syncytiotrophoblast; red arrowheads point to widened blood spaces, arrows to 432 
fibrotic areas. Images in (c) and (d) are representative of ≥3 independent mutants per line, see 433 
Methods. (e) Network created using esyN (www.esyn.org) of known interactors of L3mbtl2.  434 
 435 
Figure 3. Phenotype co-associations between embryo and placenta. (a) Enriched 436 
embryonic phenotype terms within the significantly co-associated categories of abnormal 437 
brain, blood vessel and heart morphology in mutant lines with abnormal placentas, compared 438 
to those with normal placentas (dark red: fully penetrant phenotype). For brevity, the 439 
description as “abnormal” has been removed from ontology terms. The most prevalent terms 440 
describing abnormalities observed in brain, blood vessel and heart development are shown. 441 
(b)-(d) HREM images showing embryonic phenotypes that correlate with the presence of 442 
placental defects. Upper row: normal morphology in stage-matched controls; bottom row: 443 
distinct developmental abnormalities in corresponding structures of mutants: (b) Abnormal 444 
forebrain morphology (asterisks) in Ssr2-/- embryo. (c) Double outlet right ventricle and 445 
bicuspid aortic valve in Chtop-/- embryo. Right ventricle (rv) with oblique outlet (asterisk). (d) 446 
Perimembraneous ventricular septal defect (asterisk) in Ssr2-/- embryo. I, II, III: 1st, 2nd and 3rd 447 
ventricle; aa: ascending aorta; av: aortic valve; hb: hindbrain; la, ra: left, right atrial appendix; 448 
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lDi, rDi: left, right diencephalon; lTel, rTel: left, right telencephalon; lv, rv: left, right 449 
ventricle; pv: pulmonary valve; pt: pulmonary trunk; vs: ventricle septum. Defects shown in 450 
(b)-(d) are representative of ≥3 independent mutants. 451 
 452 
Figure 4. Determining trophoblast-specific gene function. (a) Analysis of Nubpl-/- TSCs 453 
grown in self-renewal conditions (“0d”) or upon differentiation for 3 and 6 days. Data are 454 
mean +/- S.E.M. *= p<0.05; **= p<0.01; ***= p<0.001 (ANOVA with Holm-Bonferroni’s 455 
post-hoc test). Specific defects are summarised in the schematic. (b) Equivalent analysis for 456 
Bap1-/- TSCs. EPC: ectoplacental cone; GlyT: glycogen cells; SpT: spongiotrophoblast; SynT: 457 
syncytiotrophoblast (layers I and II); TGC: trophoblast giant cells. 458 
 459 
Figure 5. Dissecting lineage origins of placental phenotypes. (a) Schematic representation 460 
of the genetic constitutions of embryo (E) and placenta (P) or trophoblast (T) achieved by 461 
conditional Sox2-Cre mediated knockout (KO), and corresponding E9.5 embryos of the Nubpl 462 
strain. Phenotypes are representative of ≥12 embryos per genotype. (b) Immunofluorescence 463 
staining of corresponding placentas for MCT4 (marker of SynT-II), E-Cadherin (Cdh1) and 464 
basement membrane component Laminin (Lam; demarcates fetal blood vessels). Nuclear 465 
counterstain with DAPI. Placental defects are representative of ≥3 independent mutants per 466 
genotype. 467 
  468 
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Methods 469 
Mouse lines 470 
The majority of mouse lines were generated using the EUCOMM/KOMP knockout first 471 
conditional-ready targeted ES cell resource (http://www.mousephenotype.org/about-472 
ikmc/eucomm-program/eucomm-targeting-strategies; targeted trap “tm1a” allele and null 473 
“tm1b” allele). A few lines were generated by Crispr-Cas9 mediated gene deletion (“em1” 474 
allele). All lines were produced and maintained on a C57BL/6N genetic background at the 475 
Wellcome Trust Sanger Institute (http://www.mousephenotype.org/) as part of the DMDD 476 
project16. Use of all animals was in accordance with UK Home Office regulations, the UK 477 
Animals (Scientific Procedures) Act of 1986 and approved by the Wellcome Trust Sanger 478 
Institute’s Animal Welfare and Ethical Review Body. Gene KO lines were designated lethal if 479 
no homozygous mutants were present amongst a minimum of 28 pups at P14 and sub-viable 480 
if their proportion fell on or below 13% of total offspring from heterozygous intercrosses5. 481 
Corresponding cut-off criteria applied to the designation of sub-viability at E14.5. These 482 
“DMDD lines” were assessed at embryonic days E14.5 and/or E9.5, counting the day of the 483 
vaginal plug as E0.5. Embryos, placentas and yolk sacs were harvested; embryos were 484 
processed for HREM imaging19, placentas were fixed in 4% PFA and yolk sacs were used for 485 
genotyping.  486 
For conditional gene ablation in the embryo proper (“placental rescue”), lines were mated to 487 
Flp expressors to generate conditional “tm1c” alleles (http://www.mousephenotype.org/about-488 
ikmc/eucomm-program/eucomm-targeting-strategies), and then crossed with Sox2-Cre 489 
transgenic mice23. Informative crosses were set up between females carrying at least one 490 
conditional allele at the locus of interest and heterozygous males that additionally carried the 491 
Sox2-Cre transgene. Embryos and placentas were collected as before; genotyping was 492 
performed on embryonic tail biopsies.  493 
 494 
Histology 495 
For histological analysis, at least 3 mutant and 3 wild-type placentas from at least 2 496 
independent litters (with pairs of mutant and wild-type placentas recovered from the same 497 
litter if possible) were processed for routine paraffin histology and embedded side-by-side for 498 
each strain. Placentas of male and female conceptuses were analysed wherever possible. In all 499 
cases, tissue appearance and cellular architecture of the placentas analysed confirmed they 500 
were in viable condition even if the associated embryo had been designated as dead or dying. 501 
Consecutive 7µm sections were produced, and alternate sections mounted. A series of 502 
sections per block was processed for haematoxylin and eosin (H&E) staining, using a 503 
standard protocol (https://dmdd.org.uk/placental-analysis-protocols/). Sections through the 504 
sagittal midline were chosen for imaging, indicated at E9.5 by the remnant of the uterine 505 
lumen and at E14.5 by the site of insertion of the umbilical cord. Slides were scanned on a 506 
Hamamatsu slide scanner and images deposited at https://dmdd.org.uk. Phenotypes of 507 
placentas were assessed for each strain, blinded for strain viability scores, and recorded by at 508 
least 2 independent investigators. In cases where all 3 mutant placentas exhibited a particular 509 
abnormality, that defect was scored as a phenotype. In cases where a defect was 510 
unambiguously detected only in 2 of the initial 3 placentas analysed, an additional 2-3 mutant 511 
placentas were added to confirm the call. Overall, a phenotype was scored when at least 67% 512 
of mutant placentas exhibited that particular abnormality. Criteria for assessing yolk sac 513 
morphology encompassed apposition of the visceral yolk sac endoderm and mesoderm layers, 514 
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and the appearance of blood islands. 515 
 516 
Immunostaining and in situ hybridisation 517 
To gain a more precise view of the structural defects in mutant placentas, mutant placentas 518 
from all lines were stained for E-Cadherin (Cdh1) demarcating the labyrinthine 519 
syncytiotrophoblast (as well as parietal giant cells at E9.5) and with isolectin BSI-B4 520 
outlining labyrinthine trophoblast and decidua. In situ hybridisation for Tpbpa was used to 521 
label the spongiotrophoblast and glycogen cells. 522 
For immunostaining, sections were deparaffinised in xylene and processed through an ethanol 523 
series to PBS. Antigen retrieval was performed by boiling in 1mM EDTA pH7.2, 0.05% 524 
Tween-20 or in 10mM Na-citrate pH 6.0 buffer followed by blocking in PBS, 0.5% BSA, 525 
0.1% Tween-20. Antibodies used were anti-Cdh1 (1:100 BD Biosciences 610181), anti-526 
Laminin (1:100 Sigma L9393), anti-MCT4 (1:100 Merck Millipore AB3314P) and biotin-527 
conjugated isolectin from Bandeiraea simplicifolia BSI-B4 (1:100 Sigma L2140). Primary 528 
antibodies were detected with appropriate fluorescence or horseradish peroxidase-conjugated 529 
secondary antibodies; BSI-B4 was detected with horseradish peroxidase-conjugated 530 
Streptavidin. Nuclei were counterstained with haematoxylin or 4,6-diamidino-2-phenylindole 531 
(DAPI). In situ hybridisation for Tpbpa was performed using a standard protocol45. 532 
 533 
Phenotype Data analysis 534 
All genes associated with a placental phenotype in mutant mouse lines were selected for 535 
interaction network analysis using esyN (http://www.esyn.org). Expression data for all genes 536 
assessed in mouse mutants was obtained by meta-analysis of published RNA-seq datasets22. 537 
For testing for co-associations between embryonic and placental defects, two separate 538 
analyses were performed. Firstly we examined the phenotypes of homozygous mutant 539 
embryos where the placentas have been scored for abnormalities (122 embryos), and secondly 540 
we analysed all homozygous mutant embryos scored for mutant phenotypes (241 embryos) 541 
according to placental abnormality observed within the line, which builds on our observation 542 
that placental abnormalities were fully penetrant in almost every line. The phenotypes scored 543 
in homozygous mutant embryos were summarised into broader phenotype categories within 544 
the Mammalian Phenotype Ontology by mapping the phenotype terms recorded onto the 545 
DMDD intermediate slim as described46. 546 
Statistical analysis used Fisher’s exact test to assess for an association or increase in 547 
abnormality rate of the phenotypes when placentas were scored as abnormal. An orthogonal 548 
potential alpha-star filter was used prior to the statistical testing to reduce the multiple testing 549 
burden as recently described18. To assess the biological effect of placental abnormalities on 550 
the abnormality rate of mutant phenotypes we followed the procedure described in Karp et. 551 
al.(Ref. 18) of determining the difference in two binomial proportions and calculating the 552 
95% confidence interval using Newcombe's recommended method 10 using the ci.pd function 553 
of the R Epi package. Significance was adjusted for the effects of multiple testing using the 554 
Benjamini-Hochberg procedure to control the false discovery rate at 5%. 555 
 556 
Penetrance Analysis 557 
The MP terms assigned during annotation of the embryos were summarised into the ontology 558 
slim categories, and the penetrance score for each slim terms observed for the line calculated 559 
as previously described46. The phenotype data was analysed using the DMDD intermediate 560 
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slim terms, and lower hierarchy slims within ontology terms abnormal brain morphology, 561 
abnormal blood vessel morphology, and abnormal heart morphology (Supplementary Table 562 
3).  563 
 564 
Generation of mutant trophoblast stem cell (TSC) lines 565 
The wild-type blastocyst-derived TS-Rs26 TSC line (a kind gift of the Rossant lab, Toronto, 566 
Canada) was cultured as described previously20,21. Differentiation was induced by culturing in 567 
media lacking bFGF, Heparin and embryonic fibroblast-conditioned medium.  568 
For generation of CRISPR/Cas9-mediated knockout TSCs, gRNAs that result in frameshift 569 
mutations were designed using the CRISPR.mit.edu design software and checked for high 570 
specificity by nucleotide blast searches. gRNA sequences were cloned into the 571 
Cas9.2A.EGFP plasmid (Plasmid #48138 Addgene) and sequence-verified. Empty vector 572 
Cas9.2A.EGFP and gene-specific gRNA + Cas9.2A.EGFP constructs were used to generate 573 
vector control TSCs and KO TSCs (Extended Data Fig. 6). Transfection was carried out with 574 
Lipofectamine 2000 (ThermoFisher Scientific 11668019) reagent according to the 575 
manufacturer’s protocol. KO clones were confirmed by genotyping using primers spanning 576 
the deleted exon, and by RT-qPCR with primers within, and downstream of, the deleted exon, 577 
as shown (Extended Data Fig. 6). Five or six independent KO clones were analysed for each 578 
gene mutation.  579 
 580 
RT-qPCR expression analysis 581 
Potential defects in TSC maintenance and differentiation capacity were investigated by 582 
analysing the expression levels and dynamics of trophoblast marker genes in mutant and 583 
control TSCs in stem cell conditions and following 3 and 6 days of differentiation. Total RNA 584 
was extracted using TRI reagent (Sigma T9424), DNase-treated and 1µg used for cDNA 585 
synthesis with RevertAid H-Minus reverse transcriptase (Thermo Scientific EP0451). 586 
Quantitative (q)PCR was performed using SYBR Green Jump Start Taq Ready Mix (Sigma 587 
S4438) and intron-spanning primer pairs (Supplementary Table 4)21 on a Bio-Rad CFX96 or 588 
CFX384 thermocycler. Normalised expression levels are displayed as mean relative to the 589 
vector control sample; error bars indicate standard error of the means (S.E.M.) of at least three 590 
replicates. 591 
 592 
Transcriptomics analysis 593 
Samples were lysed in Trizol with a 5 mm stainless steel bead (Qiagen) for 4 minutes at 20 594 
Hz in a tissue lyser (Qiagen). After chloroform extraction for 30 minutes at room temperature, 595 
RNA was extracted from the aqueous phase using ethanol and a spin column (Qiagen RNeasy 596 
MinElute). After quantification (Qubit RNA BR) the sample was treated with DNAse enzyme 597 
(Qiagen) and purified over a spin column. Adapter indexed strand-specific RNA-seq libraries 598 
were generated from 1000 ng of total RNA following the dUTP method using the stranded 599 
mRNA LT sample kit (Illumina). Libraries were pooled and sequenced on Illumina HiSeq 600 
2000 in 75bp paired-end mode. Sequence data were deposited in ENA under accession 601 
ERP023265. FASTQ files were aligned to the GRCm38.p5 reference genome using TopHat 602 
(v2.0.13, options: --library-type fr-firststrand). Counts for genes were produced using htseq-603 
count (v0.6.1 options: --stranded=reverse) with the Ensembl v90 annotation as a reference. 604 
The data were assessed for technical quality (GC-content, insert size and gene body coverage) 605 
using QoRTs47 and poor quality samples removed. A variance stabilising transformation was 606 
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applied to count data for each gene using the R package DESeq2's 607 
varianceStabilizingTransformation function48. Principal components analysis (PCA) was 608 
performed on the transformed count data for each gene using R's prcomp function. 609 
 610 
Data availability 611 
All placental phenotyping data are available at https://dmdd.org.uk. Sequence data were 612 
deposited in ENA under accession ERP023265. All primers sequences are provided. 613 
 614 
  615 
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Extended data figure legends 616 
Extended Data Figure 1. Potential trophoblast gene function in mutants with placental 617 
defect. (a) Expression of trophoblast control genes and the 103 DMDD genes in trophoblast 618 
stem cells (TSCs), TSCs differentiated for 1 day (D) or 3D, and in E11.5 placentas. Log2-619 
transformed expression values of RNA-seq data are displayed. Note that all genes associated 620 
with a placental phenotype in mutants (labelled in red font) are expressed in trophoblast. (b) 621 
Frequency of placental defects annotated in mid-gestational lethal mutants (MP: 0011098) as 622 
annotated in Mouse Genome Informatics, compared to the findings in DMDD where 40/41 623 
E9.5-E14.5 lethals were found to exhibit placental abnormalities. (c) Left-hand side: Volume 624 
rendered 3D model of the surface of a wild-type (WT) embryo, staged as Theiler stage 23, 625 
and coronal section through the volume rendered model. Right-hand side: Equivalent images 626 
of a littermate E14.5 H13-/- embryo, staged as TS21. Note that the models are displayed in 627 
identical resolutions. Scale bar: 1mm. Images are representative of ≥5 embryos per genotype. 628 
(d) Network analysis using esyN (http://www.esyn.org) for all DMDD genes identified as 629 
causing a placental phenotype in mutants. BAP1 and ASXL3 are known interactors in 630 
humans. Red circles identify genes implicated in human trophoblast-based pathologies. The 631 
analysis reveals molecular nodes that appear to be of key importance for placental 632 
development. 633 
 634 
Extended Data Figure 2. Identification of placental defects by H&E histology. (a) 635 
Schematic representation of key stages and cell types in extra-embryonic development, 636 
complementing Fig. 2c, d. All: allantois; Ch: chorion; Epi: epiblast; EPC: ectoplacental cone; 637 
ExE: extra-embryonic ectoderm; PE: primitive endoderm; SynT-I, -II: syncytiotrophoblast 638 
layers I and II; TE: trophectoderm; VE: visceral endoderm. (b) Examples of E9.5 placental 639 
phenotypes. Dotted lines: boundary to maternal decidua; vertical bars: chorion trophoblast 640 
thickness; arrows in WT placenta: invagination sites of extra-embryonic mesoderm-derived 641 
blood vessels into chorionic trophoblast; arrowheads in Psph-/-: sites of chorion folding but 642 
missing blood vessels; arrowheads in Dpm1-/-: overabundant and enlarged trophoblast giant 643 
cells. (c) Examples of E14.5 placental phenotypes. Red arrows: abnormal maternal blood 644 
accumulations. Arrows in Traf2-/- and Col4a3bp-/- (incl. inset) placentas: fibrotic and/or 645 
necrotic areas; arrowheads in Chtop-/- and Pth1r-/- placentas: abnormal spongiotrophoblast 646 
inclusions. Representative mutant embryo images are also depicted. Images of mutant 647 
placentas in (b) and (c) are representative of ≥3 independent mutants per line, see Methods. 648 
 649 
Extended Data Figure 3. Co-association analysis between embryo and placenta 650 
phenotypes. (a) Mutant mouse lines were classified into those that exhibit a placental 651 
phenotype at E14.5 and those that do not. All embryos analysed by HREM imaging were 652 
tagged accordingly to either of these two groups. Enrichment of embryonic phenotype terms 653 
in mutant strains with normal or abnormal placentas is shown (dark red: fully penetrant 654 
phenotype). For brevity, the description as “abnormal” has been removed from ontology 655 
terms. (b) Significantly enriched embryonic phenotype terms in lines that exhibit an abnormal 656 
placenta (see also Supplementary Table 2) versus those with normal placenta. Following 657 
hypothesis testing using Fisher's exact test, adjusting for multiple testing using the Benjamini-658 
Hochberg method, we estimated the magnitude of the abnormal placenta effect. This was 659 
determined by calculating independent binomial proportions for the two groups of embryos 660 
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with normal (n=172) and abnormal (n=69) placenta. The percent difference between groups 661 
and the p-values are shown. 662 
 663 
Extended Data Figure 4. Specific embryonic defects are significantly correlated with the 664 
occurrence of an abnormal placenta. (a) Further, detailed co-association statistics between 665 
the occurrence of a placental phenotype and specific abnormalities in the embryo proper in 666 
DMDD lines. As before, mutant mouse lines were classified into those that exhibit a placental 667 
phenotype at E14.5 and those that do not. All embryos analysed by HREM imaging were 668 
tagged accordingly to either of these two groups. Significant differences in the frequency of 669 
specific embryonic defects was determined between these two groups, and scored for the size 670 
of the effect and for its significance. Following hypothesis testing using Fisher's exact test, 671 
adjusting for multiple testing using the Benjamini-Hochberg method, we estimated the 672 
magnitude of the abnormal placenta effect. This was determined by calculating independent 673 
binomial proportions for the two groups of embryos with normal (n=172) and abnormal 674 
(n=69) placenta. The figure shows the differences in the estimated abnormality rates of the 675 
two embryo groups, and the extent of the bars represent the 95% Newcombe confidence 676 
interval (see Methods). “TRUE” means that these associations are significant, “FALSE” that 677 
they fall below the significance threshold. Please note that some terms, such as eye 678 
development and growth/size/body region are likely a consequence of developmental 679 
retardation. However, the highlighted terms such as heart, brain and vascular system 680 
morphology are definitely based on abnormalities that are not merely due to developmental 681 
delay. (b) Same analysis as in (a) but only including those specific embryos whose placenta 682 
was analysed histologically (as opposed to all embryos per strain; n=81 and n=41 embryos 683 
having normal and abnormal placenta, respectively). Please note that the important and 684 
meaningful terms hold up to significance irrespectively. (c) HREM image of an example of a 685 
massive subcutaneous edema (asterisk) covering the entire back of a Psph-/- embryo. Volume 686 
rendered 3D model. Axial section through the level of the heart is shown as inlay. Note also 687 
the delay in developmental progress. (d) Muscular ventricular septal defect (arrowhead) in an 688 
Atp11a-/- embryo. Coronal section through volume rendered 3D model. Axial HREM-image is 689 
shown as inlay. la: left atrial appendix; lv: left ventricle; pt: pulmonary trunk; ra: right atrial 690 
appendix; rv: right ventricle; vs: ventricular septum. Embryo defects shown in (c) and (d) are 691 
representative of ≥3 independent mutants. 692 
 693 
Extended Data Figure 5. Major routes of Trophoblast Stem Cell differentiation. Diagram 694 
of the main differentiation routes of trophoblast stem cells (TSCs), including representative 695 
cell type-specific marker genes. EPC: ectoplacental cone; GlyT: glycogen cells; SpT: 696 
spongiotrophoblast; SynT: syncytiotrophoblast (layers I and II); TGC: trophoblast giant cells. 697 
 698 
Extended Data Figure 6. Selection of genes for in-depth analysis of trophoblast 699 
contribution to embryonic lethality. (a) E9.5 phenotypes of mutant placentas of the three 700 
genes (Nubpl, Bap1, Crb2) chosen for ablation in TSCs, as well as for placental rescue 701 
analysis in vivo (Fig. 5, Extended Data Figs. 8-10). Black arrows (WT placenta): fetal blood 702 
vessels penetrating into the chorionic ectoderm. Vertical bars: unpatterned appearance of 703 
chorion. Orange arrows: empty or fibrotic maternal blood spaces. Images are representative of 704 
≥3 mutants per line. (b) Details of CRISPR design and TSC clone screening strategy for the 705 
three selected genes Nubpl, Bap1 and Crb2. All targeted exons were first confirmed to be 706 
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trophoblast-expressed. RT-qPCR (performed in technical triplicate per clone) and genomic 707 
genotyping PCR analysis (performed in duplicate per sample, with results independently 708 
confirmed by RT-qPCR data) were performed on individual, single-cell expanded TSC clones 709 
to confirm homozygous knockout (KO). Of note, even though splicing may occur across the 710 
deleted exon, all CRISPR-Cas9 deletions were designed to result in a premature stop codon. 711 
RT-qPCR data are mean +/- S.E.M. of n=3 technical replicates.  712 
 713 
Extended Data Figure 7. Analysis of mutant TSCs for defects in TSC maintenance and 714 
differentiation. (a) Nubpl-/- TSC clones assessed for additional trophoblast marker genes by 715 
RT-qPCR. (b) Additional marker gene analysis on Bap1-mutant TSCs. (c) Analysis of Crb2-/- 716 
TSC clones for a phenotype in stem cell maintenance (“0d”) or during differentiation (“3d”, 717 
“6d”). No significant difference in cell morphology, growth behaviour and gene expression 718 
pattern was observed compared to wild-type (WT) vector control clones. Data are mean +/- 719 
S.E.M. *= p<0.05; **= p<0.01 (ANOVA with Holm-Bonferroni’s post-hoc test). 720 
 721 
Extended Data Figure 8. Placental rescue of Sox2-Cre mediated conditional knockout 722 
(cKO) of Nubpl. (a) Additional images of Nubpl-mutant embryos showing that a wild-type 723 
trophoblast compartment significantly rescues the developmental retardation phenotype and 724 
embryonic defects observed in the full KO at E9.5. At E11.5, Nubpl-/- embryos can still be 725 
recovered while complete KO embryos are not retrievable any more. Images are 726 
representative of ≥10 independent embryos with the corresponding genotype. (b) Histological 727 
analysis of the corresponding placentas at E11.5 shows a complete rescue of the placental 728 
defect in cKOs with a genetically functional trophoblast lineage. Sections were stained for 729 
MCT4 (SynT-II marker), E-Cadherin (Cdh1, global SynT marker) and Laminin (Lam, blood 730 
vessel basement membrane marker). Images are representative of 3 placentas per genotype. 731 
 732 
Extended Data Figure 9. Transcriptomic analysis of placentas from rescue experiments 733 
and developmental performance of Bap1 cKOs. (a) Principal component analysis of global 734 
transcriptomes of E9.5 placentas with the indicated genotype. “Res” refers to placentas from 735 
Sox2-Cre mediated conditional KOs in which the trophoblast lineage remains functional, 736 
whereas the embryo is ablated for the gene-of-interest (E:KO; T: HET). (b) Top row: E9.5 737 
embryo photos of the depicted genotypes for the Bap1 strain. The embryonic lethality of the 738 
complete Bap1 KO cannot be rescued by a functional trophoblast compartment. Images are 739 
representative of ≥12 independent embryos per genotype. Bottom row: Histological analysis 740 
of the corresponding placentas, stained as in Fig. 5b and Extended Data Fig. 8b. Arrows point 741 
to partially rescued syncytiotrophoblast loops and some vascular invaginations into the 742 
chorionic ectoderm. Yet the vascularisation of the forming labyrinth layer remains under-743 
developed compared to controls. Images are representative of 3 placentas per genotype. 744 
 745 
Extended Data Figure 10. Analysis of yolk sac morphology in Nubpl, Bap1 and Crb2 746 
mutants and developmental performance of Crb2 cKOs. (a) Immunofluorescence staining 747 
of yolk sacs for E-Cadherin (Cdh1, green) and Laminin (Lam, red) demarcating the visceral 748 
endoderm (VE) and basement membrane of the yolk sac mesoderm (YSM), respectively. Bl: 749 
Blood cells. Bap1 and Crb2 mutants show a defect characterised by the lack of attachment of 750 
the two visceral yolk sac layers (arrows). This defect cannot be rescued by Sox2-Cre mediated 751 
cKO, indicating that its cause resides in the extra-embryonic mesoderm lineage. (b) 752 
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Developmental performance of Crb2 KO and cKO embryos and analysis of placental 753 
morphology, equivalent to Extended Data Fig. 8b. No rescue of embryonic lethality or 754 
placental defects is observed in the cKOs (E: KO; T: HET). Images are representative of ≥3 755 
independent conceptuses per genotype. 756 
 757 
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